0000899243-20-010119.txt : 20200403
0000899243-20-010119.hdr.sgml : 20200403
20200403161023
ACCESSION NUMBER: 0000899243-20-010119
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200401
FILED AS OF DATE: 20200403
DATE AS OF CHANGE: 20200403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kumar Neil
CENTRAL INDEX KEY: 0001742485
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38959
FILM NUMBER: 20773438
MAIL ADDRESS:
STREET 1: C/O EIDOS THERAPEUTICS, INC.
STREET 2: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BridgeBio Pharma, Inc.
CENTRAL INDEX KEY: 0001743881
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: (650) 391-9740
MAIL ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
FORMER COMPANY:
FORMER CONFORMED NAME: BridgeBio Pharma LLC
DATE OF NAME CHANGE: 20180618
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-04-01
0
0001743881
BridgeBio Pharma, Inc.
BBIO
0001742485
Kumar Neil
C/O BRIDGEBIO PHARMA, INC.
421 KIPLING STREET
PALO ALTO
CA
94301
1
1
0
0
CEO and President
Common Stock
2020-04-01
4
S
0
27719
25.5243
D
2617653
I
See footnote
Common Stock
2020-04-01
4
S
0
20040
26.3784
D
2597613
I
See footnote
Common Stock
2020-04-01
4
S
0
12976
27.4547
D
2584637
I
See footnote
Common Stock
2020-04-01
4
S
0
1382
28.2048
D
2583255
I
See footnote
Common Stock
2020-04-02
4
S
0
15778
25.0414
D
2567477
I
See footnote
Common Stock
4685725
D
Common Stock
927686
I
See footnote
This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019.
Represents the weighted average sale price of the shares sold from $25.00 to $25.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4, 5, 6 and 7.
The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
Represents the weighted average sale price of the shares sold from $26.00 to $26.94 per share.
Represents the weighted average sale price of the shares sold from $27.00 to $27.99 per share.
Represents the weighted average sale price of the shares sold from $28.01 to $28.47 per share.
Represents the weighted average sale price of the shares sold from $25.00 to $25.30 per share.
The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
/s/ Tara Condon, Attorney-in-Fact
2020-04-03